Human Papilloma Virus Vaccine – Epidemiology – Mature Markets Data
DRG Epidemiology's coverage of the HPV vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of HPV vaccine for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's HPV vaccine forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HPV vaccine over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following HPV vaccine patient populations:
Vaccine eligible population Newly eligible for vaccine population Note: coverage may vary by country and region.
Human Papilloma Virus Vaccine - Epidemiology - Mature Markets Data
Introduction
Key Findings
Overview
HPV Vaccine Eligible Adolescent Female Population per 1,000 People in 2018 and 2038
HPV Vaccine Eligible Adolescent Male Population per 1,000 People in 2018 and 2038
HPV Vaccine Eligible Adult Female Population per 1,000 People in 2018 and 2038
HPV Vaccine Eligible Adult Male Population per 1,000 People in 2018 and 2038
Relative Sizes of the Contributing Factors to the Trend in Total Eligible Female Adolescent Population for the HPV Vaccine Over the Next 20 Years
Epidemiology Data
Methods
HPV Vaccine Eligible Population
Reference Materials
Literature Review
Studies Included in the Analysis of the Human Papillomavirus Vaccine
Studies Excluded from the Analysis of the Human Papillomavirus Vaccine
Risk/Protective Factors
Risk/Protective Factors for Human Papillomavirus Vaccine
Bibliography
Abbreviations table
Glossary
Jagriti Prasad
Jagriti Prasad, M.P.H.,is an associate epidemiologist at Clarivate. Previously, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University (U.K.) and her B.D.S. from Manipal University (India).
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
